Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

564.94 -4.24 (-0.74%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about United Therapeutics Corporation - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
United Therapeutics Corporation Reports First Quarter 2026 Financial Results
From United Therapeutics Corporation
Via Business Wire
News headline image
MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases
From MannKind
Via GlobeNewswire
News headline image
United Therapeutics Corporation Announces Retirement of Professor Raymond Dwek, C.B.E., F.R.S., From Its Board of Directors
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation to Report First Quarter 2026 Financial Results Before Market Open on Wednesday, May 6, 2026
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Presents New Data Spanning Pulmonary Hypertension Treatment, Lung Donor Expansion, and Xenotransplantation at ISHLT 2026
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP® for Treatment of Acute Liver Failure
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Announces Full Results of TETON-2 Phase 3 Clinical Trial Published in The New England Journal of Medicine
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Announces $2 Billion Stock Repurchase Authorization and Enters into $1.5 Billion Accelerated Share Repurchase Program
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation to Present at the Leerink Global Healthcare Conference
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2025 Financial Results
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation to Present at the TD Cowen 46th Annual Health Care Conference
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation to Report Fourth Quarter and Full Year 2025 Financial Results Before the Market Opens on Wednesday, February 25, 2026
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Announces Positive Results from Phase 1 Study of miroliverELAP® in Patients with Acute Liver Failure
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Announces Appointment of Kevin J. Tracey to its Board of Directors
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation to Present at Upcoming Investor Conferences
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Reports Record Third Quarter 2025 Financial Results
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation to Report Third Quarter 2025 Financial Results Before Market Open on Wednesday, October 29, 2025
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics to Feature Clinical Data at the CHEST 2025 Annual Meeting
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation to Review Data from the Successful TETON-2 Pivotal Study of Nebulized Tyvaso® in Idiopathic Pulmonary Fibrosis
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation to Present at the Bernstein 2nd Annual Healthcare Forum
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the European Respiratory Society Congress
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Announces TETON-2 Pivotal Study of Tyvaso® Meets Primary Endpoint for the Treatment of Idiopathic Pulmonary Fibrosis
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation to Report Second Quarter 2025 Financial Results Before Market Open on Wednesday, July 30, 2025
From United Therapeutics Corporation
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.